Physiomics (PYC) Competitors GBX 0.42 -0.01 (-1.41%) As of 08/22/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock PYC vs. BSFA, EVG, MTFB, DEST, VAL, GENF, RENE, ROQ, SALV, and ONCShould you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include BSF Enterprise (BSFA), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), ValiRx (VAL), Genflow Biosciences (GENF), ReNeuron Group (RENE), Roquefort Therapeutics (ROQ), SalvaRx Group (SALV), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry. Physiomics vs. Its Competitors BSF Enterprise Evgen Pharma Motif Bio Destiny Pharma ValiRx Genflow Biosciences ReNeuron Group Roquefort Therapeutics SalvaRx Group Oncimmune BSF Enterprise (LON:BSFA) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Which has preferable valuation and earnings, BSFA or PYC? Physiomics has higher revenue and earnings than BSF Enterprise. BSF Enterprise is trading at a lower price-to-earnings ratio than Physiomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBSF Enterprise£80.25K38.39-£2.04M-£1.65-1.51Physiomics£864.07K0.99-£922.82K-£0.45-0.94 Does the media favor BSFA or PYC? In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled Physiomics'average media sentiment score. Company Overall Sentiment BSF Enterprise Neutral Physiomics Neutral Which has more volatility & risk, BSFA or PYC? BSF Enterprise has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Is BSFA or PYC more profitable? Physiomics has a net margin of -106.80% compared to BSF Enterprise's net margin of -2,542.63%. BSF Enterprise's return on equity of -47.59% beat Physiomics' return on equity.Company Net Margins Return on Equity Return on Assets BSF Enterprise-2,542.63% -47.59% -20.65% Physiomics -106.80%-127.68%-76.38% SummaryPhysiomics beats BSF Enterprise on 5 of the 9 factors compared between the two stocks. Get Physiomics News Delivered to You Automatically Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYC vs. The Competition Export to ExcelMetricPhysiomicsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£860K£137.09M£5.76B£3.22BDividend Yield6.20%3.74%4.41%5.04%P/E Ratio-0.943.8731.10164.70Price / Sales0.994,057.33434.92310,111.13Price / Cash4.2113.1937.7327.93Price / Book2.0146.309.535.91Net Income-£922.82K-£90.99M£3.26B£5.89B7 Day Performance-4.34%0.42%2.10%49.53%1 Month Performance-15.35%3.51%2.82%56.39%1 Year Performance-40.40%205.46%30.56%136.21% Physiomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYCPhysiomicsN/AGBX 0.42-1.4%N/A-43.0%£860K£864.07K-0.9410BSFABSF EnterpriseN/AGBX 2.85+40.7%N/A-41.2%£3.51M£80.25K-1.7212Gap UpHigh Trading VolumeEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010MTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036DESTDestiny PharmaN/AN/AN/AN/A£2.87M£135.03K-50.0024Gap DownHigh Trading VolumeVALValiRxN/AGBX 0.55+4.8%N/A-77.5%£2.09M£27.78K-0.375,450GENFGenflow BiosciencesN/AGBX 0.61-6.2%N/A-72.0%£2.08M-£226.19K-1.155High Trading VolumeRENEReNeuron GroupN/AN/AN/AN/A£1.93M£783K-37.502Gap DownROQRoquefort TherapeuticsN/AGBX 1.34-0.7%N/A-68.1%£1.71M£2.66K-1.119Gap DownSALVSalvaRx GroupN/AN/AN/AN/A£1.65M£64.50M0.032Gap UpONCOncimmuneN/AN/AN/AN/A£1.29M£1.86M0.1352 Related Companies and Tools Related Companies BSF Enterprise Competitors Evgen Pharma Competitors Motif Bio Competitors Destiny Pharma Competitors ValiRx Competitors Genflow Biosciences Competitors ReNeuron Group Competitors Roquefort Therapeutics Competitors SalvaRx Group Competitors Oncimmune Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PYC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Physiomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access